<DOC>
	<DOCNO>NCT00880919</DOCNO>
	<brief_summary>The Primary objective study evaluate Seroquel XR treatment borderline personality disorder ( BPD ) . As many initial randomize control trial , study relatively short duration - 8 week - ass effectiveness safety maximize retention . The specific aim determine Seroquel XR superior placebo . The primary outcome measure statistically significant difference Seroquel XR compare placebo Zanarini Rating Scale Borderline Personality Disorder ( ZAN-BPD ) , objective rating scale address severity Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSM-IV ) symptoms illness . As recent development extend release form Seroquel ( Seroquel XR ) ( Schulz et al . 2007 ) , new compound may offer several advantage study . Therefore , hypothesis study dose Seroquel XR ( see ) superior placebo 8-week randomize trial assess ZAN-BPD . To achieve Primary Objective study , two dos Seroquel XR test - 150 mg/d 300 mg/d . Thus , study able assess effect Seroquel XR compare placebo explore dose effect .</brief_summary>
	<brief_title>Seroquel Extended Release ( XR ) Management Borderline Personality Disorder ( BPD )</brief_title>
	<detailed_description>The secondary objective study aim answer question regard symptom assessment , dose strategy , safety . The specific secondary objective list : 1 . Response rate : In previous study use ZAN-BPD , response define 50 % reduction ZAN-BPD score . Response rate compare Seroquel XR placebo . 2 . Other Symptom Measures : Over last twenty year , rating scale general nature use assess BPD patient clinical trial . To fully assess patient progress study , follow scale administer : Symptom Checklist 90 - Revised ( SCL-90 R ) , Montgomery Asberg Depression Rating Scale ( MADRS ) , Barratt Impulsivity Scale ( BIS ) , Schedule Interviewing Borderlines ( SIB ) , Overt Aggression Scale - Modified ( OAS-M ) , Young Mania Rating Scale ( YMRS ) , Borderline Evaluation Severity Time ( BEST ) , Global Assessment Function ( GAF ) . 3 . Side-Effects : To able report safety Seroquel XR BPD , combination objective subjective measure employ . Objectively , weight , height ( Body Mass Index ( BMI ) ) , prolactin , glucose , cholesterol triglyceride assess baseline endpoint . Objective rating movement side effect perform use Simpson Angus Scale ( SAS ) ( Simpson Angus 1970 ) , Barnes Akathisia Scale ( BAS ) ( Barnes 1989 ) , Abnormal Involuntary Movement Scale ( AIMS ) ( Guy 1976 ) , baseline endpoint . Regarding possible side effect report patient , report headache , somnolence , experience tabulate . Secondary objective data analyze continuous variable data time study , appropriate , comparison baseline endpoint make .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Consent A diagnosis borderline personality disorder ( 301.83 ) All subject ZANBPD great equal 9 randomization . Males female age 1845 year Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study Pregnancy lactation Any DSMIV Axis I disorder define inclusion criterion . The patient BPD may bipolar I disorder , schizophrenia , schizoaffective disorder , delirium , dementia . Neither may current DSMIV substance dependence . Patients , opinion investigator , pose imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrollment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine , saquinavir Use follow cytochrome P450 inducers 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomization Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . diabetes , angina pectoris , hypertension , congestive heart failure ) judge investigator Involvement planning conduct study Previous enrollment randomization treatment present study . Participation another drug trial within 4 week prior enrollment study long accordance local requirement Unstable Diabetes Mellitus An absolute neutrophil count ( ANC ) 1.5 x 109 per liter Past history lack response atypical antipsychotic medication substantial previous side effect cause exclusion . Any medical illness would interfere conduct study cause exclusion . Pregnant lactate woman woman childbearing potential use medically accept mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Borderline Personality Disorder</keyword>
	<keyword>BPD</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>quetiapine</keyword>
	<keyword>quetiapine extended-release</keyword>
</DOC>